[
  {
    "ts": null,
    "headline": "Eli Lilly Stock Back In Focus After Long Slumber",
    "summary": "Here's how we employ swing trading strategies of selling into strength, selling into weakness and cutting a loss quickly.",
    "url": "https://finnhub.io/api/news?id=bb305f72faf5b18da6bae605dbc4e35d1078f03c90cdafc2e034c93f62a154fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767996433,
      "headline": "Eli Lilly Stock Back In Focus After Long Slumber",
      "id": 138052202,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Here's how we employ swing trading strategies of selling into strength, selling into weakness and cutting a loss quickly.",
      "url": "https://finnhub.io/api/news?id=bb305f72faf5b18da6bae605dbc4e35d1078f03c90cdafc2e034c93f62a154fc"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Broke Out Following Plan To Acquire Ventyx Biosciences",
    "summary": "Highly rated Eli Lilly stock is this week's Big Cap 20 pick to watch as it attempts to take out a flat-base buy point.",
    "url": "https://finnhub.io/api/news?id=b664fd7e949ab8a3cab6bdad8c972e52fe94cbd36816ada555b2f60dd85ef04b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767984376,
      "headline": "Eli Lilly Stock Broke Out Following Plan To Acquire Ventyx Biosciences",
      "id": 138052203,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Highly rated Eli Lilly stock is this week's Big Cap 20 pick to watch as it attempts to take out a flat-base buy point.",
      "url": "https://finnhub.io/api/news?id=b664fd7e949ab8a3cab6bdad8c972e52fe94cbd36816ada555b2f60dd85ef04b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study",
    "summary": "These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.",
    "url": "https://finnhub.io/api/news?id=45793a256bc48c969e5fc4b93c4da779cf2df6e2f436745c06473ffe7907d048",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767983765,
      "headline": "Eli Lilly’s Taltz-Zepbound combo scores in late-stage PsA study",
      "id": 138052204,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "These results tout the potential of the combination as the new standard of care (SoC) for PsA patients with comorbid obesity.",
      "url": "https://finnhub.io/api/news?id=45793a256bc48c969e5fc4b93c4da779cf2df6e2f436745c06473ffe7907d048"
    }
  },
  {
    "ts": null,
    "headline": "Aktis Oncology Jumps 27% After $318 Million Upsized IPO",
    "summary": "Shares traded at $22.91 after pricing at $18, valuing the clinical-stage biotech at about $1.2 billion.",
    "url": "https://finnhub.io/api/news?id=2e41725c876564c1c84edf6b7aa6d6f8bf9bf049d82123622c0aad2aa0af0a23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767983099,
      "headline": "Aktis Oncology Jumps 27% After $318 Million Upsized IPO",
      "id": 138052205,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Shares traded at $22.91 after pricing at $18, valuing the clinical-stage biotech at about $1.2 billion.",
      "url": "https://finnhub.io/api/news?id=2e41725c876564c1c84edf6b7aa6d6f8bf9bf049d82123622c0aad2aa0af0a23"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham",
    "summary": "Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.",
    "url": "https://finnhub.io/api/news?id=4b4a93ad064f8fbb03946a73a45dc934cdd70a7b9468d7929a46263e68d88b5f",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767982030,
      "headline": "Novo Nordisk and Eli Lilly can both gain GLP-1 market share this year, says Citi's Meacham",
      "id": 138057158,
      "image": "https://image.cnbcfm.com/api/v1/image/108250847-17679995051767999502-43416902888-1080pnbcnews.jpg?v=1767999504&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Geoff Meacham, Citi analyst, joins 'Fast Money' to talk what the year ahead holds for competition in the obesity drug market.",
      "url": "https://finnhub.io/api/news?id=4b4a93ad064f8fbb03946a73a45dc934cdd70a7b9468d7929a46263e68d88b5f"
    }
  },
  {
    "ts": null,
    "headline": "Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets",
    "summary": "LOS ANGELES & BOSTON, January 09, 2026--Vida Ventures (\"Vida\"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co",
    "url": "https://finnhub.io/api/news?id=25e5d526ac759440ce79e61d0d298c9514c15e3e8ef9f5d58530e426fad0f551",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767981480,
      "headline": "Vida Ventures Congratulates Aktis Oncology on Its Entry into the Public Markets",
      "id": 138052206,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "LOS ANGELES & BOSTON, January 09, 2026--Vida Ventures (\"Vida\"), a next-generation life sciences venture firm, today congratulates Aktis Oncology (Nasdaq: AKTS), a clinical-stage biotechnology company advancing a pipeline of alpha-emitting radiopharmaceuticals for the treatment of solid tumors. Aktis raised $318 million in its initial public offering, reflecting strong investor interest, its recently announced anchor investment by Eli Lilly and Company (NYSE: LLY), and pipeline momentum as the co",
      "url": "https://finnhub.io/api/news?id=25e5d526ac759440ce79e61d0d298c9514c15e3e8ef9f5d58530e426fad0f551"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Rallies Broadly To Highs; Nvidia, AMD, Bloom Energy In Focus: Weekly Review",
    "summary": "The Dow Jones, S&P 500 and Russell 2000 all hit highs on the stock market this week. Nvidia and AMD fell despite unveiling new AI chips at CES.",
    "url": "https://finnhub.io/api/news?id=a5a035e03b60b3a40d2576b0e2d5583584ce69ab832fce13a37f9e44b2225fce",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767979229,
      "headline": "Stock Market Rallies Broadly To Highs; Nvidia, AMD, Bloom Energy In Focus: Weekly Review",
      "id": 138048029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones, S&P 500 and Russell 2000 all hit highs on the stock market this week. Nvidia and AMD fell despite unveiling new AI chips at CES.",
      "url": "https://finnhub.io/api/news?id=a5a035e03b60b3a40d2576b0e2d5583584ce69ab832fce13a37f9e44b2225fce"
    }
  },
  {
    "ts": null,
    "headline": "Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond",
    "summary": "After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.",
    "url": "https://finnhub.io/api/news?id=65850b1f4b5d1d048a2546ba7d99552d1a7009ac5713531268729a28682c8c78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767976800,
      "headline": "Betting on a Boom: 3 Healthcare ETFs for 2026 and Beyond",
      "id": 138052208,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "After a late-2025 rebound eased policy fears, healthcare ETFs like IXJ are gaining attention as investors position for a sector comeback in 2026.",
      "url": "https://finnhub.io/api/news?id=65850b1f4b5d1d048a2546ba7d99552d1a7009ac5713531268729a28682c8c78"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
    "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
    "url": "https://finnhub.io/api/news?id=06215b717963945c9963b8a712e672df556fb394ab6ba879e3642747690c939a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767975542,
      "headline": "Healthcare dealmakers head to San Francisco hoping for megamergers in 2026",
      "id": 138052209,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NEW YORK, Jan 9 (Reuters) - Healthcare dealmakers are heading to San Francisco this weekend betting on a new wave of mega-mergers in 2026 that could eclipse the industry’s standout years of 2019 and 2021 when such tie-ups approached half a trillion dollars, according to more than a dozen ​top bankers and lawyers. Ahead of the week-long 43rd annual J.",
      "url": "https://finnhub.io/api/news?id=06215b717963945c9963b8a712e672df556fb394ab6ba879e3642747690c939a"
    }
  },
  {
    "ts": null,
    "headline": "Here’s What UBS Thinks About Eli Lilly and Company (LLY)",
    "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Best Unstoppable Growth Stocks to Buy Right Now. On January 7, Michael Yee from UBS initiated coverage of Eli Lilly and Company (NYSE:LLY) with a Buy rating and raised the price target from $1,080 to $1,250. The analyst noted the company’s leadership in the obesity treatment […]",
    "url": "https://finnhub.io/api/news?id=46ee4efd24bdd40ea6190a09e32e5e4aac58b180ce0909f739bd4cc09b16454f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767974073,
      "headline": "Here’s What UBS Thinks About Eli Lilly and Company (LLY)",
      "id": 138046634,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is one of the Best Unstoppable Growth Stocks to Buy Right Now. On January 7, Michael Yee from UBS initiated coverage of Eli Lilly and Company (NYSE:LLY) with a Buy rating and raised the price target from $1,080 to $1,250. The analyst noted the company’s leadership in the obesity treatment […]",
      "url": "https://finnhub.io/api/news?id=46ee4efd24bdd40ea6190a09e32e5e4aac58b180ce0909f739bd4cc09b16454f"
    }
  },
  {
    "ts": null,
    "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
    "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
    "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767973860,
      "headline": "J&J Strikes Drug Pricing Deal With Trump, Gets Tariff Reprieve",
      "id": 138052210,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "JNJ cuts U.S. drug prices under a Trump deal, gains a tariff reprieve, and accelerates a $55 billion push to expand domestic manufacturing.",
      "url": "https://finnhub.io/api/news?id=8a744dad378981948ddd9bbf5a218db486800ed8d38efd33667ffd0ec67117ca"
    }
  },
  {
    "ts": null,
    "headline": "VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug",
    "summary": "Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.",
    "url": "https://finnhub.io/api/news?id=bf71f68ef31e92d6138999860a72dea2b7f159c2f23150506974f23c22d607a5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767970680,
      "headline": "VKTX Completes Enrollment in Phase I Maintenance Study of Obesity Drug",
      "id": 138046635,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable dosing after initial weight loss in obese adults.",
      "url": "https://finnhub.io/api/news?id=bf71f68ef31e92d6138999860a72dea2b7f159c2f23150506974f23c22d607a5"
    }
  },
  {
    "ts": null,
    "headline": "Amazon Pharmacy Begins Offering Wegovy Pill",
    "summary": "Customers with commercial insurance will pay a minimum of $25 for a one-month supply, while the cost for those without insurance starts at $149 a month.",
    "url": "https://finnhub.io/api/news?id=5e782f2af56592ef5e480cf8486095ac2566b95f315a4d59dc40c04c227397ad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767970200,
      "headline": "Amazon Pharmacy Begins Offering Wegovy Pill",
      "id": 138052211,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Customers with commercial insurance will pay a minimum of $25 for a one-month supply, while the cost for those without insurance starts at $149 a month.",
      "url": "https://finnhub.io/api/news?id=5e782f2af56592ef5e480cf8486095ac2566b95f315a4d59dc40c04c227397ad"
    }
  },
  {
    "ts": null,
    "headline": "Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery",
    "summary": "SAN FRANCISCO, January 09, 2026--Chai Discovery, the AI company building a computer-aided design suite for molecules, announces Eli Lilly and Company collaboration.",
    "url": "https://finnhub.io/api/news?id=eec84c81cc7bd7cb1b4381053059623c68db220d0bcd8d06c599d5ae22ba5080",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767967200,
      "headline": "Chai Discovery Announces Collaboration with Eli Lilly and Company to Accelerate Biologics Discovery",
      "id": 138046636,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, January 09, 2026--Chai Discovery, the AI company building a computer-aided design suite for molecules, announces Eli Lilly and Company collaboration.",
      "url": "https://finnhub.io/api/news?id=eec84c81cc7bd7cb1b4381053059623c68db220d0bcd8d06c599d5ae22ba5080"
    }
  },
  {
    "ts": null,
    "headline": "Demand For Google, Palantir Is Mere Peanuts Next To These 3 Stocks",
    "summary": "While AI stocks Google, Broadcom and Palantir remain in demand, the best mutual funds shoveled massive sums into 3 stocks.",
    "url": "https://finnhub.io/api/news?id=385ffeea7c4b82ad2511e2746d971aeec2e848c98e212a8cf798606be86ec660",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767963643,
      "headline": "Demand For Google, Palantir Is Mere Peanuts Next To These 3 Stocks",
      "id": 138045402,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "While AI stocks Google, Broadcom and Palantir remain in demand, the best mutual funds shoveled massive sums into 3 stocks.",
      "url": "https://finnhub.io/api/news?id=385ffeea7c4b82ad2511e2746d971aeec2e848c98e212a8cf798606be86ec660"
    }
  },
  {
    "ts": null,
    "headline": "Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models",
    "summary": "WALTHAM, Mass., January 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.",
    "url": "https://finnhub.io/api/news?id=26d10b243c39f94bc681b0d9fa9aca02bc970bd0258e2fc05f557182bfa33443",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767963600,
      "headline": "Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models",
      "id": 138045461,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "WALTHAM, Mass., January 09, 2026--Revvity, Inc. (NYSE: RVTY) today announced a collaboration with Eli Lilly and Company (Lilly) that expands access to Lilly’s high-quality predictive models by making Lilly TuneLab available through the Revvity Signals platform. The collaboration builds on Revvity’s recently introduced Signals XyntheticaTM offering, creating a scalable, federated framework designed to accelerate AI-enabled drug discovery.",
      "url": "https://finnhub.io/api/news?id=26d10b243c39f94bc681b0d9fa9aca02bc970bd0258e2fc05f557182bfa33443"
    }
  },
  {
    "ts": null,
    "headline": "Healthy Returns: What to expect from pharma at the JPM conference",
    "summary": "At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.",
    "url": "https://finnhub.io/api/news?id=b176745a81fadd629d60d2032e94bcf615335731dd1a1757a1b83c37313be307",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767963421,
      "headline": "Healthy Returns: What to expect from pharma at the JPM conference",
      "id": 138057238,
      "image": "https://image.cnbcfm.com/api/v1/image/108222520-17624504352025-11-06t173326z_182594845_rc24rhaozaeo_rtrmadp_0_usa-trump.jpeg?v=1767995336&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "At the JPMorgan Healthcare Conference, drugmakers are expected to roll out key business and drug pipeline updates and splashy M&A deals.",
      "url": "https://finnhub.io/api/news?id=b176745a81fadd629d60d2032e94bcf615335731dd1a1757a1b83c37313be307"
    }
  },
  {
    "ts": null,
    "headline": "Here's What We Expect From AbbVie's Immunology Segment in Q4",
    "summary": "ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.",
    "url": "https://finnhub.io/api/news?id=09b911cafe130d129e73462fa37b066d995c4dce1085f38c82dc1a5f6a7d8e29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767962640,
      "headline": "Here's What We Expect From AbbVie's Immunology Segment in Q4",
      "id": 138045462,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "ABBV's Q4 outlook hinges on surging Skyrizi and Rinvoq demand, as investors watch immunology sales to offset Humira's past loss of exclusivity.",
      "url": "https://finnhub.io/api/news?id=09b911cafe130d129e73462fa37b066d995c4dce1085f38c82dc1a5f6a7d8e29"
    }
  },
  {
    "ts": null,
    "headline": "Schrodinger to offer Eli Lilly's AI drug discovery platform on its software",
    "summary": "By Sneha S K Jan 9 (Reuters) - Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.",
    "url": "https://finnhub.io/api/news?id=5115489f60d17e2f164303986f6842a4a31c1888858f24f2a8be2acad136b126",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767960225,
      "headline": "Schrodinger to offer Eli Lilly's AI drug discovery platform on its software",
      "id": 138045464,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "By Sneha S K Jan 9 (Reuters) - Schrodinger said on Friday it is collaborating with Eli Lilly to offer the pharmaceutical major's AI-based platform, TuneLab, on its drug designing software.",
      "url": "https://finnhub.io/api/news?id=5115489f60d17e2f164303986f6842a4a31c1888858f24f2a8be2acad136b126"
    }
  },
  {
    "ts": null,
    "headline": "Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign",
    "summary": "NEW YORK, January 09, 2026--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows.",
    "url": "https://finnhub.io/api/news?id=9ded78f8625139d83d39c59104b8297ce207447ed25cd3ff344d75c33afdf2dd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767960000,
      "headline": "Schrödinger Partners with Lilly to Make TuneLab Platform Available in LiveDesign",
      "id": 138045465,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "NEW YORK, January 09, 2026--Schrödinger, Inc. (Nasdaq: SDGR) today announced a collaboration with Lilly TuneLab™, a platform launched by Eli Lilly and Company (Lilly) designed to accelerate drug discovery and development by providing access to advanced artificial intelligence (AI) capabilities. TuneLab will be made available in LiveDesign, Schrödinger’s widely used enterprise informatics platform, as a priority interface for participating biotech companies to access TuneLab workflows.",
      "url": "https://finnhub.io/api/news?id=9ded78f8625139d83d39c59104b8297ce207447ed25cd3ff344d75c33afdf2dd"
    }
  },
  {
    "ts": null,
    "headline": "Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal",
    "summary": "Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.",
    "url": "https://finnhub.io/api/news?id=cd30537d2698b702d9f948de455a87c310a75485b5e316e12cf07881a09b9c57",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767958080,
      "headline": "Insmed’s ‘ginormous’ lung drug sales; J&J’s US pricing deal",
      "id": 138052212,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Insmed’s Brinsupri blew past consensus estimates in its first full quarter on the market. Elsewhere, J&J inked pharma’s latest deal with the Trump administration and Madrigal licensed a Pfizer drug.",
      "url": "https://finnhub.io/api/news?id=cd30537d2698b702d9f948de455a87c310a75485b5e316e12cf07881a09b9c57"
    }
  },
  {
    "ts": null,
    "headline": "Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight loss pill",
    "summary": "Eligible customers with insurance can pay as little as $25 for a one-month supply of the drug, while cash-paying options start at $149 a month, Amazon said.",
    "url": "https://finnhub.io/api/news?id=ca1c6365dd82e1fcada929f72c965ffe2dbffd839b4749061ac880877cedaef3",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767957716,
      "headline": "Amazon Pharmacy starts offering Novo Nordisk's Wegovy weight loss pill",
      "id": 138047531,
      "image": "https://image.cnbcfm.com/api/v1/image/107386525-1710277103163-gettyimages-1342267772-281619final.jpeg?v=1767978225&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Eligible customers with insurance can pay as little as $25 for a one-month supply of the drug, while cash-paying options start at $149 a month, Amazon said.",
      "url": "https://finnhub.io/api/news?id=ca1c6365dd82e1fcada929f72c965ffe2dbffd839b4749061ac880877cedaef3"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and JD.com have been highlighted as Zacks Bull and Bear of the Day",
    "summary": "Eli Lilly's obesity drugs Mounjaro and Zepbound are driving explosive revenue growth, strengthening its dominance as demand accelerates worldwide.",
    "url": "https://finnhub.io/api/news?id=32bef52e2309c6e1ac0be9f4f341558b587bf3ceb7bb736bfcbf34b3aa831d81",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767951900,
      "headline": "Eli Lilly and JD.com have been highlighted as Zacks Bull and Bear of the Day",
      "id": 138045466,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly's obesity drugs Mounjaro and Zepbound are driving explosive revenue growth, strengthening its dominance as demand accelerates worldwide.",
      "url": "https://finnhub.io/api/news?id=32bef52e2309c6e1ac0be9f4f341558b587bf3ceb7bb736bfcbf34b3aa831d81"
    }
  },
  {
    "ts": null,
    "headline": "Bull of the Day: Eli Lilly (LLY)",
    "summary": "Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.",
    "url": "https://finnhub.io/api/news?id=133dc909b1f03c430b136cf18c76980cee5e093f4e307e93603eead92841ce3f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767949200,
      "headline": "Bull of the Day: Eli Lilly (LLY)",
      "id": 138044514,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly has solidified itself as a global pharma titan. With leading drugs and a massive obesity market, Lilly is poised to be a juggernaut for years to come.",
      "url": "https://finnhub.io/api/news?id=133dc909b1f03c430b136cf18c76980cee5e093f4e307e93603eead92841ce3f"
    }
  },
  {
    "ts": null,
    "headline": "A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year",
    "summary": "Europe's best performing stock in 2025, Abivax, could be snapped up any day now, analysts say.",
    "url": "https://finnhub.io/api/news?id=cc51c9aede062004e513ac24dc4422785f4f1d88fe05c91bc25359ab1c9950e1",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767941677,
      "headline": "A little-known biotech stock has become a prime takeover target after surging nearly 1,700% last year",
      "id": 138047616,
      "image": "https://image.cnbcfm.com/api/v1/image/108249930-1767883114856-gettyimages-1457781967-_x3m2814.jpeg?v=1767883140&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "Europe's best performing stock in 2025, Abivax, could be snapped up any day now, analysts say.",
      "url": "https://finnhub.io/api/news?id=cc51c9aede062004e513ac24dc4422785f4f1d88fe05c91bc25359ab1c9950e1"
    }
  }
]